SG10201914027VA - Antibody producing non-human mammals - Google Patents

Antibody producing non-human mammals

Info

Publication number
SG10201914027VA
SG10201914027VA SG10201914027VA SG10201914027VA SG10201914027VA SG 10201914027V A SG10201914027V A SG 10201914027VA SG 10201914027V A SG10201914027V A SG 10201914027VA SG 10201914027V A SG10201914027V A SG 10201914027VA SG 10201914027V A SG10201914027V A SG 10201914027VA
Authority
SG
Singapore
Prior art keywords
human mammals
antibody producing
producing non
mammals
antibody
Prior art date
Application number
SG10201914027VA
Other languages
English (en)
Inventor
Erwin Houtzager
Rui Daniel Pinto
Ton Logtenberg
Mark Throsby
Robert Kramer
Kruif Cornelis De
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41280336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201914027V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG10201914027VA publication Critical patent/SG10201914027VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201914027VA 2008-06-27 2009-06-29 Antibody producing non-human mammals SG10201914027VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2008050430 2008-06-27

Publications (1)

Publication Number Publication Date
SG10201914027VA true SG10201914027VA (en) 2020-03-30

Family

ID=41280336

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201408500RA SG10201408500RA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914019YA SG10201914019YA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201408500RA SG10201408500RA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914019YA SG10201914019YA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Country Status (22)

Country Link
EP (6) EP2556747B1 (enrdf_load_stackoverflow)
JP (6) JP5749161B2 (enrdf_load_stackoverflow)
KR (5) KR20110029156A (enrdf_load_stackoverflow)
CN (3) CN102123582B (enrdf_load_stackoverflow)
AU (1) AU2009263082C1 (enrdf_load_stackoverflow)
CA (1) CA2729095C (enrdf_load_stackoverflow)
CY (2) CY1114830T1 (enrdf_load_stackoverflow)
DK (3) DK2147594T3 (enrdf_load_stackoverflow)
ES (3) ES2906344T3 (enrdf_load_stackoverflow)
HR (2) HRP20220205T1 (enrdf_load_stackoverflow)
HU (1) HUE057994T2 (enrdf_load_stackoverflow)
LT (1) LT3456190T (enrdf_load_stackoverflow)
MX (1) MX2010014542A (enrdf_load_stackoverflow)
NZ (1) NZ590118A (enrdf_load_stackoverflow)
PL (2) PL3456190T3 (enrdf_load_stackoverflow)
PT (3) PT2147594E (enrdf_load_stackoverflow)
RS (2) RS62925B1 (enrdf_load_stackoverflow)
RU (2) RU2731084C2 (enrdf_load_stackoverflow)
SG (3) SG10201914027VA (enrdf_load_stackoverflow)
SI (2) SI2147594T1 (enrdf_load_stackoverflow)
WO (1) WO2009157771A2 (enrdf_load_stackoverflow)
ZA (1) ZA201009312B (enrdf_load_stackoverflow)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
RS62925B1 (sr) * 2008-06-27 2022-03-31 Merus Nv Transgena murinska životinja koja proizvodi antitela
CA3038954A1 (en) 2008-09-30 2010-04-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
DK2792236T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
DK2553100T3 (en) 2010-03-31 2017-10-23 Ablexis Llc REPLACING NON-HUMAN ANIMALS TO CREATE CHIMERARY ANTIBODIES
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
WO2012018610A2 (en) 2010-07-26 2012-02-09 Trianni, Inc. Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
LT2601298T (lt) * 2010-08-02 2017-03-10 Regeneron Pharmaceuticals, Inc. Pelė, kuri gamina rišančius baltymus, apimančius vl domenus
SI3865581T1 (sl) * 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201403223PA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
EP3165086A1 (en) * 2012-03-06 2017-05-10 Regeneron Pharmaceuticals, Inc. Common light chain mouse
CN104302171B (zh) 2012-03-16 2017-05-03 瑞泽恩制药公司 表达ph敏感性免疫球蛋白序列的非人动物
SG11201405164QA (en) 2012-03-16 2014-10-30 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MX381210B (es) 2012-03-16 2025-03-12 Regeneron Pharma Anticuerpos con cadena ligera modificada con histidina por ingenieria genetica y animales no humanos geneticamente modificados para generarlos.
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SI2838918T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul
RU2014153674A (ru) * 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
CN103571872B (zh) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
SI2900694T1 (sl) 2012-09-27 2018-12-31 Merus N.V. Bispecifična IGG protitelesa kot vključitelji T-celic
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
HRP20230490T1 (hr) * 2013-03-13 2023-08-04 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
HUE033272T2 (en) * 2013-10-15 2017-11-28 Regeneron Pharma Humanized il-15 animals
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
SG11201607109QA (en) 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv Antibody that binds erbb-2 and erbb-3
CA2942697A1 (en) 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
GB2526867A (en) * 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
HUE042039T2 (hu) 2015-07-10 2019-06-28 Merus Nv Humán CD3 kötõ antitest
KR20180038055A (ko) 2015-08-24 2018-04-13 트리아니, 인코포레이티드 면역글로불린의 강화된 생산
MD3365373T2 (ro) 2015-10-23 2021-08-31 Merus Nv Molecule de legare care inhibă dezvoltarea cancerului
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
IL260743B2 (en) 2016-02-04 2024-03-01 Trianni Inc Advanced production of antibodies
PT4218408T (pt) 2016-06-03 2025-03-26 Regeneron Pharma Roedores que expressam desoxinucleotidil-transferase terminal exógena
BR112019002771A2 (pt) 2016-08-12 2019-05-14 Oxitec Ltd polinucleotídeo de módulo de controle de união de doublesex, sistema de expressão de gene, plasmídeo vetor de expressão, inseto geneticamente engenheirado, métodos para produzir insetos geneticamente engenheirados, para cultivar seletivamente insetos macho geneticamente engenheirados, para reduzir uma população de inseto selvagem, para criar um mosquito aedes aegypti transgênico e para detectar a presença de uma molécula de dna, local alvo cromossômico de aedes aegypti, mosquito aedes aegypti geneticamente engenheirado, molécula de dna, e, kit de detecção de dna.
EP3515951B1 (en) 2016-09-23 2024-02-28 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CN110637083A (zh) * 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
MX2019011658A (es) 2017-03-31 2019-11-18 Merus Nv Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
EA201992522A1 (ru) 2017-05-17 2020-04-22 Мерус Н.В. КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW201920264A (zh) 2017-07-06 2019-06-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
CA3068933A1 (en) 2017-07-06 2019-01-10 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
EA202090004A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Биспецифические антитела против pd-1 и против tim-3
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
EA202090215A1 (ru) 2017-08-09 2020-07-01 Мерус Н.В. АНТИТЕЛА, СВЯЗЫВАЮЩИЕ EGFR И cMET
CN111432838A (zh) 2017-12-01 2020-07-17 美勒斯公司 使用双特异性抗体和il-15进行联合治疗
TWI827567B (zh) * 2017-12-05 2024-01-01 美商再生元醫藥公司 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
IL277353B2 (en) 2018-03-24 2025-05-01 Regeneron Pharma Non-human animals genetically modified to produce therapeutic antibodies against peptide-MHC complexes, methods for their preparation and uses thereof
JP7603578B2 (ja) 2018-03-30 2024-12-20 メルス ナムローゼ フェンノートシャップ 多価抗体
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
EP3813521B1 (en) * 2018-06-08 2025-03-05 Crystal Bioscience Inc. Transgenic chicken for producing diversified antibodies that have the same light chain ii
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3898685A1 (en) 2018-12-20 2021-10-27 Merus N.V. Clec12axcd3 bispecific antibodies and methods for the treatment of disease
WO2020132557A1 (en) 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
WO2020141974A1 (en) 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
SG11202106705UA (en) * 2018-12-31 2021-07-29 Merus Nv Mixed binding domains
MX2021008796A (es) 2019-01-22 2021-11-12 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos.
PH12021552001A1 (en) 2019-02-14 2022-09-19 Merus Nv Producing compositions comprising two or more antibodies
MA54944A (fr) 2019-02-14 2021-12-22 Merus Nv Combinaisons de fractions de liaison se liant à egfr, her2 et her3
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
TWI862565B (zh) * 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
CA3139402A1 (en) 2019-05-09 2020-11-12 Merus N.V. Variant domains for multimerizing proteins and separation thereof
KR20220030956A (ko) * 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
MX2022000971A (es) * 2019-07-30 2022-02-14 Ono Pharmaceutical Co Anticuerpo biespecifico.
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
BR112022003143A2 (pt) 2019-08-19 2022-05-17 Merus Nv Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i.
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
EP4269433A3 (en) 2019-12-24 2024-05-22 Merus N.V. Tgf-beta-rii binding proteins
KR20220133196A (ko) 2020-01-29 2022-10-04 메뤼스 엔.페. 면역 세포 관여 효과를 조절하기 위한 수단 및 방법
KR20230005281A (ko) 2020-04-24 2023-01-09 메뤼스 엔.페. Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
JP7714992B2 (ja) * 2020-10-02 2025-07-30 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
IL303633A (en) 2020-12-15 2023-08-01 Merus Nv Treatment of cancers with an antibody that binds lgr5 and egfr
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN116710486A (zh) 2020-12-16 2023-09-05 美勒斯公司 用于治疗癌症的多特异性抗体
CA3202123A1 (en) 2020-12-18 2022-06-23 Alexander Berthold Hendrik Bakker Antibody composition
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
CA3237654A1 (en) 2021-10-06 2023-04-13 Merus N.V. Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
WO2023146394A1 (en) 2022-01-25 2023-08-03 Merus N.V. Combination therapy for the treatment of cancer
KR20240151848A (ko) 2022-03-07 2024-10-18 메뤼스 엔.페. Egfr 및 cmet에 결합하는 항체를 사용한 치료
JP2025509312A (ja) 2022-03-07 2025-04-11 メルス ナムローゼ フェンノートシャップ ＥＧＦＲ及びｃＭＥＴに結合する抗体を含む併用療法
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
AU2023408531A1 (en) 2022-12-23 2025-07-17 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
AU2023418141A1 (en) 2022-12-28 2025-07-17 Merus N.V. Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (da) * 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2124967C (en) * 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
AU751659B2 (en) * 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
AU754699C (en) * 1998-03-30 2003-05-15 Research Development Foundation Corticotropin releasing factor receptor 1-deficient mice
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002309063B8 (en) * 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
ES2442615T5 (es) * 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
EP1439234A1 (en) * 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
EP2395016A3 (en) * 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
NZ548828A (en) 2004-01-20 2009-07-31 Merus B V Mixtures of binding proteins
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
EP1874817A2 (en) * 2005-04-29 2008-01-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
JP5514539B2 (ja) * 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
WO2007143168A2 (en) 2006-06-02 2007-12-13 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
RS61650B1 (sr) 2006-10-02 2021-04-29 Regeneron Pharma Visokoafinitetna humana antitela za humani il-4 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
RS62925B1 (sr) * 2008-06-27 2022-03-31 Merus Nv Transgena murinska životinja koja proizvodi antitela
RS59001B1 (sr) * 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem

Also Published As

Publication number Publication date
DK3456190T3 (da) 2022-02-14
CN112481300A (zh) 2021-03-12
EP2147594A1 (en) 2010-01-27
EP2147594B1 (en) 2013-11-13
EP2556747A3 (en) 2016-08-03
RS62925B1 (sr) 2022-03-31
PL2147594T3 (pl) 2014-04-30
HRP20220205T1 (hr) 2022-05-27
RU2011102962A (ru) 2012-08-10
HK1154463A1 (zh) 2012-04-27
HRP20140139T1 (hr) 2014-03-14
SG10201408500RA (en) 2015-01-29
EP2556747B1 (en) 2020-12-02
ES2906344T3 (es) 2022-04-18
PL3456190T3 (pl) 2022-06-06
SI2147594T1 (sl) 2014-02-28
KR102306491B1 (ko) 2021-09-29
DK2556747T3 (da) 2021-02-15
KR20200057093A (ko) 2020-05-25
CN102123582B (zh) 2015-09-30
JP2022188085A (ja) 2022-12-20
AU2009263082B2 (en) 2014-03-20
PT2147594E (pt) 2014-02-17
EP2556747A2 (en) 2013-02-13
KR20170066688A (ko) 2017-06-14
RU2020127564A (ru) 2022-02-21
WO2009157771A2 (en) 2009-12-30
AU2009263082C1 (en) 2018-11-01
KR102112655B1 (ko) 2020-05-19
CA2729095A1 (en) 2009-12-30
WO2009157771A3 (en) 2010-02-18
ZA201009312B (en) 2011-08-31
KR20190025068A (ko) 2019-03-08
KR20110029156A (ko) 2011-03-22
RU2015119670A3 (enrdf_load_stackoverflow) 2019-01-22
JP2024063038A (ja) 2024-05-10
CY1114830T1 (el) 2016-12-14
LT3456190T (lt) 2022-03-10
DK2147594T3 (da) 2014-02-10
PT2556747T (pt) 2021-02-15
CN105191863A (zh) 2015-12-30
SG10201914019YA (en) 2020-03-30
JP2020191882A (ja) 2020-12-03
CN105191863B (zh) 2020-12-22
ES2853226T3 (es) 2021-09-15
RU2559524C2 (ru) 2015-08-10
RU2015119670A (ru) 2015-12-10
AU2009263082A1 (en) 2009-12-30
EP3456193A1 (en) 2019-03-20
RS53146B (en) 2014-06-30
CA2729095C (en) 2018-12-04
KR102261586B1 (ko) 2021-06-08
EP3456192A1 (en) 2019-03-20
JP7439201B2 (ja) 2024-02-27
JP2017121256A (ja) 2017-07-13
EP3456192B1 (en) 2025-09-03
JP6824807B2 (ja) 2021-02-03
JP7242611B2 (ja) 2023-03-20
KR101990228B1 (ko) 2019-06-17
JP2011525808A (ja) 2011-09-29
EP3456190B1 (en) 2021-11-24
RU2020127564A3 (enrdf_load_stackoverflow) 2022-02-21
KR20140127914A (ko) 2014-11-04
EP3456191A1 (en) 2019-03-20
JP5749161B2 (ja) 2015-07-15
AU2009263082B9 (en) 2014-07-17
RU2731084C2 (ru) 2020-08-28
NZ590118A (en) 2012-10-26
CY1125119T1 (el) 2023-06-09
PT3456190T (pt) 2022-02-15
CN102123582A (zh) 2011-07-13
HUE057994T2 (hu) 2022-06-28
EP3456190A1 (en) 2019-03-20
ES2445193T3 (es) 2014-02-28
SI3456190T1 (sl) 2022-06-30
JP2015156871A (ja) 2015-09-03
MX2010014542A (es) 2011-04-05

Similar Documents

Publication Publication Date Title
SG10201914019YA (en) Antibody producing non-human mammals
ZA201102119B (en) Improved antibody libraies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
IL212701A0 (en) Improved anti-cd19 antibodies
ZA201103586B (en) C-met antibodies
SI2262831T1 (sl) Protitelesa anti-properdina
SG10201601279SA (en) Monoclonal Antibody STRO-4
SG10201403703XA (en) Methods of producing humanized non-human mammals
GB0821100D0 (en) Antibodies
IL207581A0 (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB2473934A8 (en) Antibody
GB0911770D0 (en) Antibody
EP2264071A4 (en) ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION
FI20085308A0 (fi) Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä
GB0820307D0 (en) Antibody production
GB0815963D0 (en) Antibody production
PL384301A1 (pl) Urządzenie do produkcji biopaliwa
GB0819113D0 (en) An antibody
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody
GB0804687D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody